VERADERMICS

Corporate Overview
1H 2023

Transforming Medical Dermatology

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.

DERMATOLOGISTS DEVELOPING FIRST-IN-CLASS DRUGS FOR DERMATOLOGY

Founded by dermatologists, the company is leveraging its executive team's proven front-line clinical experience to identify and develop innovative therapeutics that address specific patient needs and solve pervasive treatment challenges in dermatology practice. Guided by a steadfast commitment to tackling real-world patient and clinician problems that limit the current standard of care for common skin conditions, Veradermics is acting with urgency to advance a pipeline of diverse, first-in-class, single-molecule product candidates with demonstrated mechanisms of action.

ADDRESSING PERVASIVE TREATMENT CHALLENGES IN DERMATOLOGY

Veradermics has cultivated a dermatology-focused pipeline of five novel product candidates for large-market conditions seen in adults and children that are overdue for new treatment approaches including common warts (verruca vulgaris), molluscum contagiosum, alopecia areata, androgenetic alopecia (pattern hair loss), and atopic dermatitis.

PROGRAM INDICATION	MOA DELIVERY	PRE-IND	PHASE 1	PHASE 2	PHASE 3
VDMN **Common Warts**	Candida Antigen Extract Immunotherapy Dissolvable Microarray				
VDMC **Molluscum Contagiosum**	Topical New Chemical Entity Antiviral				
VDAA **Alopecia Areata**	Confidential Topical against Clinically Validated Target				
VDPHL **Pattern Hair Loss**	Confidential Oral against Clinically Validated Target				
VDAD **Atopic Dermatitis**	Oral New Chemical Entity Against Clinically Validated Target				

VDMN: PATIENT-FRIENDLY, INJECTION-FREE APPROACH FOR COMMON WARTS

The company's lead product candidate, VDMN, offers the potential to transform the standard of care for common warts (verruca vulgaris), which affect 22 million Americans and are responsible for millions of clinical visits in the U.S. every year. There are no FDA-approved prescription treatments for common warts. VDMN is a novel, injection-free approach to treating common warts in the form of a dissolvable microarray patch incorporating Candida Antigen Extract — which has been successfully used to treat warts for over 20 years with efficacy that exceeds current standard of care. VDMN is painlessly applied to the wart and worn for less than five minutes. Applications are repeated every three weeks until wart resolution. Because of VDMN's unique immunologic mechanism of action, patients suffering from multiple warts may only have to treat a single wart to treat all their warts. Because VDMN is a potential first licensure biologic with pediatric labeling, it can expect 12.5 years of regulatory exclusivity after BLA approval. Additionally, VDMN is protected by a broad portfolio of IP that covers the microarray technology and formulation.

VDMC: FIRST-IN-CLASS TREATMENT FOR MOLLUSCUM

Verademics is also focused on bringing new value to patients and clinicians in the treatment of molluscum contagiosum. Molluscum is a poxvirus infection that affects six million Americans, results in one million doctors' office visits annually in the U.S., and has no FDA-approved therapeutics. The company is developing VDMC as a first-in-class topical antiviral that was discovered by leading pox virus experts at the University of Pennsylvania and works against a specific molecular target. VDMC was designed to maximize safety for use in the pediatric population affected by molluscum. Specifically, VDMC has anticipated minimal systemic absorption with topical application, is not expected to result in permanent scarring, and attacks a pox virus target that does not significantly overlap with human DNA synthesis machinery.

VDAA: TARGETING THE BURDEN IN AUTOIMMUNE HAIR LOSS

Verademics' program in alopecia areata provides further evidence of the company's commitment to finding solutions to common skin conditions that are overdue for clinical change. Alopecia areata, an autoimmune hair loss disease that affects one million adults and 200,000 children in the U.S., has a significant quality of life burden and is associated with depression and suicidal ideation. There are no FDA-approved topical treatments for alopecia areata. Verademics is developing VDAA as a first-in-class topical treatment that can be applied monthly for all severities of alopecia areata and is supported by more than 40 years of data. VDAA has decades of real-world safety and efficacy support in the published literature and should not require routine laboratory monitoring with use.

VERADERMICS

AT A GLANCE

EXECUTIVE MANAGEMENT

Reid Waldman, M.D.
Chief Executive Officer and Board Member

Tim Durso, M.D.
President and Board Member

Jane Grant-Kels, M.D.
Chief Medical Officer and Board Member

EXTERNAL BOARD MEMBERS

Vlad Coric, M.D.
Chairman and Chief Executive Officer
Biohaven

John W. Childs
Chairman and Partner
J.W. Childs Associates, LP

INVESTORS

J.W. Childs Associates, LP

Connecticut Innovations

Werth Family Investment Associates LLC

Chemwerth

Therapeutics Inc.

North Point Advisors

Backed by 25+ Physician Investors

VERADERMICS

85 Memorial Road, #415
West Hartford, CT 06107

MEDIA / INVESTOR CONTACT

Reid Waldman, M.D., CEO
rwaldman@verademics.com